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Various strategies are currently employed to potentiate human CTL-mediated immune responses in cancer 
patients with the goal of impairing tumor progressions. Although, in vitro studies put forth the notion that human 
CTL are very sensitive to antigenic stimulation and elicit rapid cytotoxicity responses1–4, it is known that tumor 
cells exhibit various mechanisms of resistance to CTL attack5,6 and that the tumor microenvironment is plagued 
by multiple mechanisms of immune cell inhibition7,8. It is therefore critical to develop an optimized metrics of 
human CTL efficacy against cancer cells. A better metrics of CTL responses might be instrumental to adapt ther-
apeutic strategies based on CTL adoptive transfer and limit tumor escape from immune surveillance9.
In this context, a key unresolved question concerns the definition of human CTL per capita killing rates. 
Understanding the inner dynamics of human CTL/tumor cell interaction is indeed crucial to define how efficient 
individual CTL are when facing cancer cells for a prolonged time. Unfortunately, gaining in vitro data on human 
CTL per capita killing requires visualization of a large number of individual CTL/target cell interactions using 
time-lapse microscopy optimized for single cell inspection10–12. #is approach is technically challenging and com-
plex to extrapolate to clinical settings.
To overcome such a technical bottleneck, we designed an agent-based model, calibrated on experimental 
measurements, which accurately reproduces human CTL/tumor cell interactions taking place within the cul-
ture dish. #is in silico approach allows to perform data analysis and modeling of in vitro results obtained at the 
population level and to extrapolate them to the single cell level. It also allows to dissect individual cell behaviors 
that could not be inferred by standard in vitro assays. Furthermore, various complex scenarios of CTL/target cell 
interaction (e.g. cytotoxicity assays lasting several days, investigation of a large spectrum of effector/target (E/T) 
ratios, etc.) can be explored in silico.
Computational studies addressing the behavior of CTL and target cells during their competitive interaction in 
vitro and in vivo have been previously released. Indeed, complex multi-step immune cell/tumor cell interactions 
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within the highly heterogeneous tumor microenvironment can be mathematically modelled as predator/prey 
dynamical systems in which several global parameters of the immune response can influence the success of one 
of the two populations over the other13–17. In the present study aiming at defining CTL per capita killing, we focus 
our investigation on the events occurring at the contact site between CTL and target cells during the very rapid 
process of lethal hit delivery18–20.
Our in silico model provides several lines of evidence that extend experimental results. First, it reveals CTL 
super-killing activity within the whole population, thus supporting previously reported experimental data 
obtained at the single cell level10. Second, it points out that CTL per capita killing is higher at lower E/T ratios. 
#ird, it highlights a global weakness of CTL to control tumor growth over prolonged time even at high E/T 
ratios. Finally, an important prediction of the model is that sequential addition of fresh CTL cohorts improves 
CTL efficacy in controlling tumor growth. We implemented this protocol experimentally and obtained in vivo 
results that confirm model prediction.
Results
ƥ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
Ǥ In order to investigate whether and how individual CTL in a whole population might influence each
other in their capacity to kill target cells, we designed an experimental protocol allowing to study killing efficacy 
during overnight interaction at very low E/T ratios. Human CTL were conjugated with target cells (either con-
ventional target cells such as EBV-B cells or melanoma cells) pulsed with the antigenic peptide or le& unpulsed. 
Cytotoxicity was measured by FACS analysis.
In line with our previously reported data5,10,21, we observed that, while killing of conventional target cells could 
be detected even at very low E/T ratios (<0.5) when a sustained interaction time was allowed, melanoma cells 
were relatively resistant to CTL attack for a prolonged time (Fig. 1a).
#e analysis also provided the intriguing result that the per capita CTL killing efficacy was much higher at low 
E/T ratios when compared to high E/T ratios. Figure 1b shows the average per capita killing kctl calculated with 
the following formula:
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where nkt is the number of target cells killed and nctl is the number of CTL. Results show that at 0.01 E/T ratio each 
CTL could kill on average 12 conventional target cells and 3.3 melanoma cells while the per capita killing rates 
sharply decreased with increasing E/T ratios.
Taken together, the above results indicate that the density of CTL negatively correlates with their individual 
capacity to kill target cells.
ǦǤ We next
built an agent-based model that could reproduce the behavior of both CTL and target cells within an in silico set 
up. As shown in Movies 1 and 2 and Fig. 2a, the computational model qualitatively re-created the in vitro exper-
imental conditions at different E/T ratios within a virtual culture well. Once calibrated, the model was then used 
to evaluate various CTL/target cell interaction scenarios. (Model description is provided in Methods Section and 
Supplementary Fig. 1. Parameters used in this study are given in Supplementary Table 1).
Interestingly, Fig. 2b,c show that the model was able to quantitatively fit experimental data only if a proba-
bilistic inactivation of CTL was implemented during the cytotoxicity process. #e model also allowed a detailed 
Figure 1. Density of CTL negatively correlates with their individual capacity to kill target cells. Population 
scale (a) and per capita (b) killing efficacy of human CTL during overnight interaction with melanoma cells or 
conventional target cells. Target cells were pulsed with the antigenic peptide and co-cultured for 18 hours with 
antigen-specific CTL at the indicated E/T ratios. Cytotoxicity was evaluated by flow cytometry using 7-AAD 
uptake by target cells. Cytotoxicity is expressed as fold increase over corresponding basal death. Data are from 
at least three independent experiments and are represented as mean ± SD. Unpaired student’s t-test using the 
GraphPad Prism so&ware (version6; GraphPad) was used to determine the statistical significance of differences 
between groups. ***P < 0.001, **P < 0.0, *P < 0.05.
temporal monitoring of the culture well by providing “real time” statistics of per capita CTL killing activity. It 
showed increasing killing efficacy at low CTL densities (Fig. 2d).
Further analysis showed that at very low CTL/melanoma cell ratios (Fig. 3a–c) a large fraction of the CTL pop-
ulation killed more than 5 target cells with few CTL killing up to 17–18 target cells. At higher E/T ratios (Fig. 3d,e) 
this fraction progressively decreased and disappeared. Similar results were observed with conventional target 
cells although, under these conditions, the global numbers of killed targets were higher (Supplementary Fig. 2).
#e above observations are in line with our previous experimental results, obtained at single cell level, show-
ing that a fraction of CTL, within a clonal population, behaves as highly efficient killer cells by killing more than 
10 target cells10. #e present computational results extend our previous data by showing that super-killer behavior 
is more pronounced at very low E/T ratios.
Taken together the above results show that our model accurately reproduces human CTL killing assays in 
silico. In line with experimental data, the model supports the existence of an intrinsic mechanism controlling 
CTL-mediated cytotoxicity. Furthermore, the above results allow retrieving individual cell behaviors starting 
from experimental data that were obtained in population.
Figure 2. Simulation of killing assays and detailed temporal analysis of per capita killing efficacy using 
an agent-based model. Panel (a) shows a snapshot taken from a simulated interaction at 1:1 E/T ratio (see 
Supplementary Movie 1). (b,c) Comparison of in vitro and in silico data of killing efficacy either without (b) or 
with (c) probabilistic inactivation of CTL during in silico simulations. (d) Temporal statistics of per capita CTL 
killing activity accessible using the computational model. Results shown in (b,c) correspond to mean +/− SD of 
20 independent runs. Results in (d) correspond to mean of 20 independent runs.
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experimental and computational results showing that CTL density inversely correlates with individual cell killing 
efficacy prompted us to look at the “optimal E/T ratio” sufficient to control tumor target cell growth without using 
an excess of CTL. As shown in Fig. 4a, at an E/T cell ratio close to 1:1, an efficient control of the tumor growth was 
observed over a period of 18 hours. More precisely, the optimal ratio for 18 hour simulations was 0.615 E/T ratio 
(with 999.65 target cells remaining a&er 18 hour interaction with CTL, averaged on 20 runs, std = 27.2653144). 
#is value has been obtained by parameter sampling with 0.005 steps between 0.5 and 1 E/T ratio. To verify 
whether this optimal E/T ratio would be effective also at longer times of interaction, we performed computer–
assisted simulation of CTL/target cell interactions lasting up to 360 hours (15 days), a time incompatible with 
classical experimental killing assays. #is analysis showed that tumor cells tended to outnumber CTL during 
Figure 3. Computational modeling highlights deficiency of individual CTL killing capacity at high CTL 
densities. #e panels show the population repartition of CTL killing efficacy at different E/T ratios. #e fraction 
of CTL within the whole population killing a high number of melanoma cells increases with the decrease of the 
E/T ratio. #e E/T ratios simulated in the model are indicated in panels. Results correspond to mean +/− SD of 
20 independent runs.
prolonged time (Fig. 4b). Indeed, statistical analysis of multiple simulations showed that, even at E/T ratios as 
high as 16:1, a small fraction of melanoma target cells was still alive. A very high E/T ratio (>24:1) was necessary 
to efficiently control tumor growth over 360 hours.
Together, the above results indicate that while the “optimal E/T ratio” can provide a score for the killing effi-
cacy of a given CTL population within a defined time window, it is not an absolute value indicating the number 
of CTL required to durably control the growth of a given target cell population. Indeed, the capacity of CTL to 
control resistant tumor target cells over a prolonged time is limited even at high E/T ratios.
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Ǥ We employed our computational model to explore various CTL/tumor cell interaction sce-
narios with the aim of improving protocols allowing tumor cell growth control over a prolonged time. Since our 
experimental and computational observations revealed that high cell densities limit the per capita CTL efficacy, 
we investigated the possibility that deferring the interaction between CTL and tumor cells might enhance tumor 
control. To this end, we simulated the sequential addition of fresh cohorts of CTL at different time intervals. As 
shown in Fig. 4c–f, at equal numbers of CTL added, we observed a better control of tumor growth if CTL were 
Figure 4. Prolonged time simulations show an intrinsic weakness of CTL in controlling tumor growth that can 
be overcome by sequential addition of fresh CTL cohorts. Panel (a) shows the number of target cells alive a&er 
18 hour simulated co-culture at different E/T ratios. Panel (b) shows the limited control of tumor growth during 
15 days of simulated co-culture. Panels (c–f) show the benefit of multiple additions of fresh CTL cohorts to the 
simulated culture. Results correspond to mean +/− SD of 20 independent runs. Statistical comparison of data 
shown in panels (c–f) was performed using Wilcoxon test and is presented in Supplementary Table 2.
added sequentially instead of being all present at the beginning of the culture. Supplementary Table 2 statisti-
cally confirms the previous analysis by the mean of a Wilcoxon test comparing the efficacy in tumor cell control 
exerted by equivalent numbers of CTL either all present at time 0 or sequentially added: p-values of each com-
parison are lower  than 10−2.
All in all, the above-presented computational data revealed a clear advantage of protocols involving sequential 
CTL addition during prolonged time over protocols based on initial large cohorts of CTL.
We intended to experimentally verify this forecast, however to reproduce such scenarios in vitro was techni-
cally challenging because of the impossibility to perform in vitro killing assays lasting up to 10–15 days. To over-
come this limitation and experimentally evaluate the model forecast, we investigated the impact that sequential 
addition of antigen-specific CTL might have on the control of sub-cutaneous B16 mouse melanoma nodules. 
#is approach was chosen to analyze tumor control over a time window comparable to that of the computational 
model and to verify model prediction in an in vivo set up.
As shown in Fig. 5, sequential CTL addition resulted in a significant enhancement of tumor growth control 
compared to initial injection of an equivalent number of CTL.
Taken together, our results reveal that the pace at which antigen-specific CTL cohorts join the tumor microen-
vironment has a major impact on the efficacy of tumor elimination.
Discussion
In the present study, we release a new computational tool calibrated on experimental data that describes the inner 
dynamics of competitive CTL/tumor cell interaction by zooming into a virtual culture dish with an unprece-
dented resolution. #is tool allows to rapidly explore a broad range of cell/cell interaction scenarios and pro-
vides a stepping-stone to inspire strategies enhancing CTL efficacy over prolonged time frames. We report that 
fine-tuning of killer cell density during prolonged interaction with target cells is of central importance in enhanc-
ing tumor cell control by CTL.
An important aspect of our interdisciplinary study is that it developed as teamwork. Biologists and computer 
scientists designed initial experiments while experimental results alimented the computational model. In turn, 
computational model predictions inspired further experiments.
Figure 5. Sequential addition of fresh CTL cohorts results in better control of tumor growth in vivo. C57BL/6 
mice were injected subcutaneously with 2 × 106 OVA+ B16 tumor cells. On day 5, mice were adoptively 
transferred with 6 × 106 activated OT-I CD8+ T cells either in 1 injection or in 3 injections of 2 × 106 each with 
a time interval of 4 hours. A third group served as control with no CTL injection. Tumor growth was monitored 
over time. Data are from three independent experiments performed on 3 mice per group and are represented as 
mean +/− SD. Data was analyzed by two-way repeated measures ANOVA using the GraphPad Prism so&ware. 
***P < 0.0001.
To investigate the efficacy of CTL in killing conventional or tumoral target cells, we used, as cellular models, 
EBV-B cells and melanoma cells that were either pulsed with strong antigenic ligands (peptides of the human 
cytomegalovirus protein pp65) or le& unpulsed before conjugation with cognate CTL. #is strategy was chosen to 
avoid the possibility that obtained results could be biased by sub-optimal CTL activation when facing tumor tar-
get cells. Virus specific CTL are indeed fully activated to lethal hit delivery when interacting with peptide-pulsed 
melanoma cells5,21.
More than 20 years ago, others and ourselves put forth the notion of the exquisite sensitivity of T cell anti-
gen recognition. It is now well established that T lymphocytes can be activated by an extremely small number 
of specific peptide/MHC complexes displayed on the antigen presenting cell surface22–24. In human CTL, we 
showed that lethal hit delivery has an extraordinarily low threshold since it can be saturated at concentrations of 
antigenic peptide used for pulsing much lower ([pM/nM] concentrations2) than those required to activate CTL to 
IFN-γ production ([µM] concentrations). More recently, we put forth the notion of lytic and stimulatory synapses 
formed by CTL when interacting with peptide pulsed target cells. We showed that CTL can form lytic synapses 
and exhibit saturating cytotoxicity responses when interacting with target cells pulsed with very low antigen con-
centrations. Conversely, CTL require a much stronger antigenic stimulation to form stimulatory synapses and to 
be activated to IFN-γ production3.
M.M. Davis and coworkers substantially contributed to this field by employing methods allowing to directly
visualize peptide/MHC complexes present at the immunological synapses formed by both helper T cells and 
CTL. #eir seminal studies showed that both helper and cytotoxic T cells activate their biological function when 
detecting as few as 3 to 12 specific peptide/MHC complexes at the immunological synapse4,25,26.
#e notion that human CTL exhibit an extremely low threshold for activation to lethal hit delivery and are 
fully activated to cytotoxicity when interacting with peptide-pulsed target cells allowed us to implement in our 
computational model a scenario in which each initial encounter between a CTL (still in its activated state) and a 
target cell would result in productive triggering of cytotoxic response against that specific target.
#e agent-based model designed in this study appears to be a valuable tool to improve the comprehension of 
the complex interactions taking place during CTL-mediated cytotoxicity since it allows to extract data on individ-
ual cell behaviors from standard experimental protocols performed at whole population scale.
Although equation-based models can valuably represent cellular interactions and have been successfully 
employed to describe several aspects of the immune response including CTL-mediated target cell cytotoxic-
ity27–29, we preferred an agent-based model since such an approach is flexible and easy to adapt to different exper-
imental scenarios30–32. Another important feature of our approach is that it is accessible to biologists who can 
therefore actively participate to the model design. Such a synergy is crucial to make sure that generated models 
are compliant with the observed reality. Also, when compared to standard cellular automata33, the use of contin-
uous virtual environment allows finer simulation of cell mobility and, consequently of cell-cell dynamic inter-
actions, which are the corner stone of cytotoxicity. Although the model could have allowed us to study spatial 
dynamics, we mainly focused on CTL density rather than on the characteristics of cell motility and interactions. 
#is choice was justified by the necessity of creating a computational scenario as adherent to our experimental 
protocol as possible. Finally, we paid a particular attention to calibrate the model all-along its development with 
detailed experimental data. #is procedure led to the emergence of realistic cell behaviors at the whole population 
scale and, in turn, to obtain accurate forecasts of the outcome of cell-cell interactions.
An unresolved question in CTL biology concerns the definition of the per capita killing efficacy at the single 
cell level under different CTL/target cell interaction scenarios. Although recent studies described protocols to 
measure individual CTL killing rates both in vitro and in vivo10,12,34, measurements of killing capacity at the single 
cell level are technically challenging and difficult to adapt to different experimental conditions. Having validated 
the capacity of the model to accurately reproduce CTL/target cell behaviors and to mimic different interaction 
scenarios, we used our computational analysis to estimate the per capita killing efficacy of the individual cells 
within the virtual culture plate.
Another advantage of our model is that it can be extended to the third dimension to mimic different scenarios 
of 3-D CTL/target cell interaction, thus providing a description of cellular interactions closer to those occurring 
in vivo without the need of performing complex 3-D imaging experiments.
A first observation that stemmed from our in silico reproduction of CTL/target interactions was that the model 
could not fit experimental data without implementing an inhibitory mechanism of the CTL killing activity, which 
is in agreement with previous computational analyses and is therefore somehow expected13,14,35,36. However, it is 
interesting to note that in our system, the observation that CTL density has a negative impact on their cytotoxic 
function, comes mainly from our experimental data (Fig. 1), while the computational analysis permitted us to 
extend experimental data.
#e observation that in the absence of a probabilistic inactivation of CTL the difference in resistance to cyto-
toxicity between conventional target cells and melanoma cells (well documented in vitro) is rapidly abolished 
in silico might appear intriguing (Fig. 2b). However, it should be noted that, with the increase of E/T ratios, this 
difference tends to be progressively reduced also in experimental conditions21. At E/T ratios as high as 10:1 to 
20:1, the number of target cells that can be killed is expected to converge towards values close to 100% for both 
conventional target cells and melanoma cells (see blue line in Fig. 4f depicting a 16:1 E/T ratio). In the absence of 
probabilistic inactivation of CTL this process is dramatically enhanced. For this reason the percentage of killed 
cells rapidly reaches 100% in both cell types also at low E/T ratios.
#e molecular nature of such inhibitory mechanism(s) is presently elusive. It is tempting to speculate that 
inhibitory metabolites might be released by dying target cells or by activated CTL to locally extinguish the kill-
ing activity. #e observed limitation of cytotoxic function at high cell density appears to be independent from 
the nature of the employed target cells and to be an intrinsic characteristic of CTL. Indeed, we observed a sim-
ilar trend in CTL per capita killing both with melanoma cells and conventional target cells. Even though this 
mechanism has to be further experimentally explored, its description might be of major importance in under-
standing regulation of CTL-mediated immune responses.
#e model we propose can potentially be upgraded into new models based on clinical data that might be 
instrumental to evaluate experimental protocols aiming at improving the killing efficacy of CTL in patients. An 
example of the potential of our combined experimental and computational approaches is our observation that 
progressive adjustment of CTL densities might enhance cytotoxic activity. We show in silico and confirm in vivo 
that sequential re-addition of fresh CTL cohorts is more efficient to control tumor growth when compared to a 
unique initial CTL cohort. It is interesting to speculate that these results might have relevance for CAR-T cell 
therapeutic strategies. Although these therapies are very promising and are providing objective clinical amelio-
ration in a fraction of patients affected by hematological malignancies, they need optimization. In particular, the 
dosing strategies might be adjusted to provide a longer duration of CAR-T cell therapeutic effect while limiting 
the adverse effects of the treatment37. More generally, our results obtained in a binary cellular model, might 
inspire new research aiming at defining per capita killing in clinical settings by exploring more complex scenarios 
of CTL-mediated tumor immune-surveillance.
Since, the model is effective to forecast long-term outcomes of CTL/tumor cell interactions, it is tempting 
to speculate that the model might be instrumental to evaluate more complex scenarios in which additional cell 
types, known to modulate immune surveillance against tumors (such as tumor associated macrophages, regu-
latory T cells, etc.), might be introduced in order to evaluate their quantitative contribution to tumor escape. 
Further experimental and computational research will be required to address this important point. In order to 
envisage modelling complex scenarios in immunotherapy, it will be necessary to experimentally measure the 
impact that “additional players” of the immune response might have on our binary cellular model and then pro-
gressively enrich the complexity of the model with new data generated from specifically designed experiments.
So far, several computational studies addressed various aspects of the complex dynamics of immune surveil-
lance against cancer. For instance, Alfonso et al. used agent-based modeling to simulate the inflammatory process 
in breast tissues which involves many types of cells (myoepithelial, luminal, effectors and regulators) acting in a 
2-D discrete environment36. Authors used both data from literature and data extracted from whole-slide imaging
immunohistochemistry to calibrate the model and were able to improve the prognostic of the patients based on
analysis performed using the model. In Hatzikirou et al.13, the authors propose an equation-based framework at
the cell population scale to analyze the impact of immune recruitment via vascularization in tumors and propose
a new therapeutic approach for personalized tumor profiling. To this end, the model’s parameters are explored in
order to study the behavior of the simulated tumor-effector system in various conditions leading to the conclusion
that an optimal effector concentration range exists in order to better control tumor growth. In line with our paper,
D’Onofrio et al. proposed a general mathematical framework that models the tumor-immune system competi-
tion and proposes new therapeutic strategies based on periodic re-addition or infusion therapies14. #e novelty
and the peculiarity of our study, when compared to previous ones, consists in our strategy to focus the investi-
gation essentially on the events occurring at a well-defined step of CTL fight against tumor target cells: lethal hit
delivery18–20. We accumulated over the years a profound knowledge about human CTL activation and cytotoxic
responses10,18,19,21. #is allowed us to feed the model with parameters that were all measured experimentally. #e
combined results from experimental and computational strategies, unexpectedly revealed that the density of CTL
can influence their per capita killing independently of signals derived from additional components of the immune
system.
Although the approach we chose in our study might appear simplistic, it has the advantage of allowing con-
stant cross-fertilization among experimental and computational approaches. Moreover and importantly, our 
approach is justified by a considerable amount of recently published data showing that, in clinical settings, the 
number of CD8+ T cells present in the tumor microenvironment and their activation status, are major parameters 
in predicting disease progression and response to immunotherapy in cancer patients38,39. #ere is therefore strong 
need to combine experimental and computational efforts to better understand the process of CTL-mediated 
cytotoxicity.
In conclusion, our study releases a computer model that reproduces in silico cytotoxicity assays and contrib-
utes to a better understanding of the fine balance between human CTL efficacy and tumor target cell resistance 
measured in cytotoxicity assays. As above-discussed, our findings might be instrumental for translational studies 
aiming at establishing/improving personalized therapeutic protocols based on the potentiation of CTL efficacy 
against cancer.
Material and Methods
Ǥ Human T cell clones and target cells were generated and maintained as described in5 and as
detailed below. Human CD8+ Tcell lines were purified from healthy donor blood samples using the RosetteSep 
Human CD8+ T Cell Enrichment Cocktail (StemCell Technologies). For cloning, HLA-A2-restricted CD8+ T 
cells specific for the NLVPMVATV peptide or the VLAELVKQI peptide of the cytomegalovirus protein pp65 
were single cell sorted into 96-U-bottom plates using a BD FACSAria II cell sorter using tetramer staining. Cells 
were cultured in RPMI 1640 medium supplemented with 8% human AB serum (PAA), minimum essential 
amino acids, HEPES and sodium pyruvate (Invitrogen), 100 IU/ml human rIL-2 and 50 ng/ml human rIL-15. 
CD8+ Tcell clones were stimulated in complete RPMI/HS medium containing 1 µg/ml PHA with 1 × 106 per ml 
35 Gy irradiated allogeneic peripheral blood mononuclear cells (isolated on Ficoll Paque Gradient from buffy 
coats of healthy donors) and 1 × 105 per ml 70 Gy irradiated EBV-transformed B cells. Re-stimulation of clones 
was performed every 2–3 weeks. Blood samples were collected and processed following standard ethical proce-
dures (Helsinki protocol), a&er obtaining written informed consent from each donor and approval by the French 
Ministry of the Research (AC-2014-2384).
#e following HLA-A2+ cell lines were used as target cells: EBV-transformed B cells (JY) and D10 cells (iso-
lated from metastatic melanoma patients, kindly provided by Dr G. Spagnoli, Basel, Switzerland5).
To determine target cell division rate, live target cell number was measured by manually counting cells in the 
culture wells using a Neubauer chamber and trypan blue dye exclusion, every 24 hours. JY and D10 cultures were 
respectively started with 0.25 × 106 and 0.9 × 106 cells per well. In parallel experiments, cells were fixed and per-
meabilized in 70% ethanol for 30 min on ice and stained with DAPI at 1 µg/ml (Sigma D9542), followed by FACS 
analysis. #e duration of cell cycle phases was estimated using a mathematical workflow described in Bernard et al.40.
B16 mouse melanoma cell line was a kind gi& from Dr. P. Bousso (Institute Pasteur, Paris).
6-8-week-old C57BL/6 mice were purchased from Charles River. OT-I TCR, Ubi-GFP, Ubi-GFP RAG1−/−
OT-I TCR mice were bred in the animal facility of the Institut Pasteur under specific-pathogen free conditions. 
All animal studies were approved by the Pasteur Institute Safety Committee in accordance with French and 
European guidelines (CETEA 2013-0077). Mice were examined every day and sacrificed in case of prostration, 
tousled-hair or weakness.
Ǥ Cytotoxicity assay was performed as described in5 and as detailed below. Target cells were
le& unpulsed or pulsed with 10 µM antigenic peptide during 2 h at 37 °C/5% CO2, washed three times and sub-
sequently transferred to a 96-well U-bottom plate at 25 × 103 cells per 100 µl RPMI, 5% FCS/HEPES. CTL were 
previously stained with 0.1 µM CMFDA for 15 min at 37 °C/5% CO2, washed and added to the target cells at indi-
cated CTL/target cell ratio in 100 µl RPMI, 5% FCS/HEPES. Cells were pelleted for 1 min, 455 g and incubated at 
37 °C/5% CO2 for the indicated time points. Before FACS analysis, 0.25 µg 7-aminoactinomycin D (7-AAD; BD 
Biosciences) was added to each sample to measure the percentage of dead targets.
In vivoǤ OVA expressing B16 Tumor cells were harvested at exponential phase, and 2 × 106
tumor cells were re-suspended in 50 µl of PBS and injected subcutaneously in mouse leg.
Mouse CD8+ T cells were purified from the lymph nodes of Ubiquitin C-GFP × OT-I TCR Tg mice using the 
depleting CD8 isolation kit (Milteny) and were activated in plates coated with 2.5 µg anti-CD3 mAb (clone 17.A2) 
in the presence of 2.5 µg/mL soluble anti-CD28 mAb (clone 37.51) for 48 hours. T cells were then cultured for 3–4 
additional days in the presence of 25 IU/mL rIL-2 (Roche).
Recipient mice were adoptively transferred with 6 × 106 purified in vitro activated OT-I CD8+ T cells on day 
5 post tumor injection either in a single injection of 6 × 106 cells or three injections of 2 × 106 cells every 4 hours. 
Tumor volumes were recorded every 2–3 days. #ese methods were adapted from41.
Ǥ We used agent-based modeling to simulate interactions between target cells and CTL
ongoing into a culture dish. In the model, individual cells are represented by independent agents. #ey can be of 
two types: target cells or CTL. Cell behaviors have been designed thanks to extensive interaction between com-
puter scientists and immunologists with the aim to capture the biological knowledge of the complex system to 
simulate. State-transition diagrams, shown in Supplementary Fig. 1, illustrate the resulting cell behaviors. Time is 
discretized with a ∆t time steps, chosen small to improve mechanical stability of the simulation. Cells are acting 
in a virtual continuous physical world in which cell-cell membrane adhesions are simulated with 
mass-spring-damper system. Collisions and cell-cell adhesion are simulated. #e virtual culture well is initialized 
with cells of both types (numbers depend on E/T ratio), all aggregated in the center of the dish to simulate centrif-
ugation. #e aim is indeed to carefully reproduce the centrifugation step employed in the in vitro experimental 
protocols. All parameters used in simulation are provided in Supplementary Table 1.
Target cells. When created, target cells start cycling. At the beginning, durations of the target cell cycle phase 
are randomly generated with normal distribution. Average and standard deviation of the durations are given by 
experimental data obtained in cell cultures in exponential growth phase. #e target cell division rate and cell cycle 
parameters are calibrated using in vitro measurements. Supplementary Fig. 3 shows that the model fits in expo-
nential growth conditions for both types of target cells.
Cell cycle is split into two phases: G1/S and G2/M phases. Target cells double their mass and volume during 
the G2/M phase. When mitosis phase ends, the mother cell cycle is reset with new duration parameters to mimic 
the generation of a first daughter cell; a second daughter cell is created next to the first one with a division plan 
randomly generated.
When two target cells are entering in physical contact, they adhere while continuing cycling. When a target 
cell enters in contact with a CTL, they adhere, but target cell stops cycling to enter in defense state. During the 
defense state, the survival duration of the target cell is reduced at each time step. #e survival duration is cali-
brated using parameter fitting based on experimental data from killing assays.
#e reduction of survival duration is directly proportional to the number of CTL the target is in contact with. 
#e total survival duration of a target cell corresponds to the amount of time necessary for one CTL to kill one 
target cell. During the defense state, CTL within a range of a given distance have a given probability to be disabled 
at each time step. #e target cell can switch back to cycling state if all CTL that are interacting with the target cell 
get disabled or loose contact. However, when the survival duration is equal to zero, the defense state ends: the 
target cell dies and disappears from the simulated environment. All parameters corresponding to this state have 
been established by doing parameter fitting on experimental data from killing assays.
Cytotoxic T Lymphocytes. When created, CTLs are starting in a random motion state to randomly explore 
the environment. If two CTL enter in contact, they do not adhere and interpenetration is solved by the physics 
engine. Random motion is defined as a Brownian motion with parameters derived from Christophe et al.33 When 
a CTL enters in contact with a target cell, they adhere. #e CTL switches to an attacking state during which the 
CTL reduces the survival duration of the target cell. In the meantime, the CTL can be disabled during contact 
with target cell as described above. #is killing activity can be stopped by target cell death or by CTL inactivation. 
When CTL get disabled, they do not die, but switch back to random motion and remain in this state until the end 
of the simulation.
Model implementation. #e model is implemented using C++ 14 programming language. #e datasets gener-
ated and analyzed in this study, together with generated code, are available upon request.
Parameter sampling. #e disabling radius Rd and disabling probability Pd parameters of the model were techni-
cally complex to obtain experimentally. We have performed a parameter sampling on both these parameters 
measuring the distance to experimental data at the different E/T ratio available and for both cell lines in the ranges 
R [50, 400]d ∈  with steps of 12.5 µm and ∈ . .P [0 00025, 0 01]d  with steps of 0.00025. #e best couple (Rd, Pd) has 
been selected using the mean square distance to experimental data on the available E/T ratios (0.01, 0.05, 0.1, 0.5 
and 1.0), both cell lines (conventional and melanoma cells) averaged on 10 runs per line and per ratio.
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